BioLife shares employee video from Repligen CEO on pending merger

BioLife Solutions, Inc. filed a Form 8-K dated August 3, 2026 disclosing communications sent to its workforce about its pending combination with Repligen Corporation. On that date, BioLife management sent employees an email that included a video from Repligen leadership meant to give staff more background on Repligen and the planned mergers.¹ The filing attaches a transcript of that video as Exhibit 99.1 and the accompanying email as Exhibit 99.2.

In the video, Repligen President and CEO Olivier Loeillot addressed BioLife staff directly. He introduced himself as Repligen's President and CEO and said he wanted to speak with employees personally about the moment.¹ He described BioLife's CryoStor products, saying the platform supports commercially approved cell therapies and most U.S. cell-based therapy trials.¹ He also outlined Repligen's background, noting the company was founded in 1981 by two scientists and is now headquartered in Waltham, Massachusetts.¹

On the deal timeline, Loeillot said the transaction still requires regulatory and shareholder approvals, with closing expected in the fourth quarter of this year.¹ He added that until closing, Repligen and BioLife will keep operating as separate, independent companies.¹

The underlying merger agreement, first disclosed earlier, provides that BioLife entered a merger agreement with Repligen and two Repligen merger subsidiaries under which BioLife will first merge into a Repligen subsidiary and survive as a wholly owned Repligen subsidiary, then merge again so that the second merger subsidiary survives as a direct, wholly owned subsidiary of Repligen.¹

The filing states that Repligen plans to file a Form S-4 registration statement with the SEC covering the mergers, which will include a BioLife proxy statement and a Repligen prospectus.¹